US5496924A
(en)
*
|
1985-11-27 |
1996-03-05 |
Hoechst Aktiengesellschaft |
Fusion protein comprising an interleukin-2 fragment ballast portion
|
US5359035A
(en)
*
|
1985-12-21 |
1994-10-25 |
Hoechst Aktiengesellschaft |
Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
|
DE3607835A1
(de)
*
|
1986-03-10 |
1987-09-24 |
Boehringer Ingelheim Int |
Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
|
EP0237019A3
(de)
*
|
1986-03-14 |
1988-03-09 |
Toray Industries, Inc. |
Konjugiertes Interferon und dessen Herstellung unter Verwendung eines rekombinanten Gens
|
JP2561122B2
(ja)
*
|
1988-04-13 |
1996-12-04 |
寳酒造株式会社 |
機能性ポリペプチド
|
US5705478A
(en)
*
|
1989-02-21 |
1998-01-06 |
Washington University |
Covalently linked β subunits of the glycoprotein hormones as antagonists
|
WO1990012877A1
(en)
*
|
1989-04-19 |
1990-11-01 |
Cetus Corporation |
Multifunctional m-csf proteins and genes encoding therefor
|
US7264944B1
(en)
|
1989-04-21 |
2007-09-04 |
Amgen Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
ES2238070T3
(es)
*
|
1989-04-21 |
2005-08-16 |
Amgen Inc. |
Receptor del tnf, proteina ligante del tnf y adn codante para estos.
|
AU651949B2
(en)
*
|
1989-07-14 |
1994-08-11 |
American Cyanamid Company |
Cytokine and hormone carriers for conjugate vaccines
|
US6143866A
(en)
*
|
1989-07-18 |
2000-11-07 |
Amgen, Inc. |
Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
US5108910A
(en)
*
|
1989-08-22 |
1992-04-28 |
Immunex Corporation |
DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
|
US5073627A
(en)
*
|
1989-08-22 |
1991-12-17 |
Immunex Corporation |
Fusion proteins comprising GM-CSF and IL-3
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
US5395760A
(en)
*
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
NZ235148A
(en)
*
|
1989-09-05 |
1991-12-23 |
Immunex Corp |
Tumour necrosis factor receptor protein and dna sequences
|
US5945397A
(en)
*
|
1989-09-05 |
1999-08-31 |
Immunex Corporation |
Purified p75 (type II) tumor necrosis factor receptor polypeptides
|
ATE236249T1
(de)
|
1989-09-12 |
2003-04-15 |
Hoffmann La Roche |
Tfn-bindende proteine
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
ZA912490B
(en)
*
|
1990-04-19 |
1992-12-30 |
Res Dev Foundation |
Antibody conjugates for treatment of neoplastic disease
|
US5273889A
(en)
*
|
1990-08-22 |
1993-12-28 |
University Of Saskatchewan |
Gamma-iterferon-leukotoxin gene fusions and uses thereof
|
US5238823A
(en)
*
|
1990-08-22 |
1993-08-24 |
Veterinary Infectious Disease Organization |
Interleukin-2-leukotoxin gene fusions and uses thereof
|
US5594107A
(en)
*
|
1990-08-22 |
1997-01-14 |
University Of Saskatchewan |
Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
|
DK0546124T4
(da)
*
|
1990-08-29 |
2003-05-19 |
Inst Genetics Llc |
Hæmatopoiese-stimulatorer med flere domæner
|
WO1992006117A1
(en)
*
|
1990-09-28 |
1992-04-16 |
Seragen, Inc. |
Inhibiting unwanted immune responses
|
WO1992006116A1
(en)
*
|
1990-09-28 |
1992-04-16 |
Ortho Pharmaceutical Corporation |
Hybrid growth factors
|
US5674849A
(en)
*
|
1990-10-24 |
1997-10-07 |
Allelix Biopharmaceuticals Inc. |
Anti-viral compositions
|
US5650150A
(en)
*
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
WO1992013548A1
(en)
*
|
1991-02-08 |
1992-08-20 |
Immunex Corporation |
Method of inhibiting replication of hiv in macrophages
|
GEP20033082B
(en)
*
|
1991-03-15 |
2003-10-27 |
Amgen Inc |
Pegylation of Polypeptides
|
SE468050C
(sv)
*
|
1991-03-15 |
1998-04-27 |
Pharmacia & Upjohn Ab |
Rekombinant derivat av human faktor VIII
|
US5661008A
(en)
*
|
1991-03-15 |
1997-08-26 |
Kabi Pharmacia Ab |
Recombinant human factor VIII derivatives
|
EP0512733A2
(de)
*
|
1991-05-03 |
1992-11-11 |
Washington University |
Modifizierter Komplementsystemregler
|
US5856115A
(en)
*
|
1991-05-24 |
1999-01-05 |
Fred Hutchinson Cancer Research Center |
Assay for identification therapeutic agents
|
AU666866B2
(en)
*
|
1991-08-30 |
1996-02-29 |
Fred Hutchinson Cancer Research Center |
Hybrid cytokines
|
US6171824B1
(en)
*
|
1991-08-30 |
2001-01-09 |
Fred Hutchinson Cancer Research Center |
Hybrid cytokines
|
US6028177A
(en)
*
|
1991-10-04 |
2000-02-22 |
Washington University |
Methods of detecting single-chain forms of the glycoprotein hormone quartet
|
US5376367A
(en)
*
|
1991-11-22 |
1994-12-27 |
Immunex Corporation |
Fusion proteins comprising MGF and IL-3
|
JPH07508639A
(ja)
*
|
1992-03-30 |
1995-09-28 |
イミュネックス・コーポレーション |
腫瘍壊死因子受容体を含む融合蛋白質
|
EP0642585B1
(de)
*
|
1992-05-18 |
2005-12-28 |
Genentech, Inc. |
Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden
|
US5763584A
(en)
*
|
1992-05-18 |
1998-06-09 |
Genentech, Inc. |
Receptor activation with hepatocyte growth factor agonists
|
ATE237808T1
(de)
*
|
1992-10-21 |
2003-05-15 |
Stefan Miltenyi |
Direkte auswahl von zellen durch ein aussheidungsprodukt
|
US7166423B1
(en)
*
|
1992-10-21 |
2007-01-23 |
Miltenyi Biotec Gmbh |
Direct selection of cells by secretion product
|
IL107642A0
(en)
*
|
1992-11-20 |
1994-02-27 |
Amgen Inc |
Progenitor b cell stimulating factor
|
US5772992A
(en)
*
|
1992-11-24 |
1998-06-30 |
G.D. Searle & Co. |
Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
|
US6153183A
(en)
*
|
1992-11-24 |
2000-11-28 |
G. D. Searle & Company |
Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
|
ZA942206B
(en)
*
|
1993-04-01 |
1994-10-31 |
Amgen Inc |
Biologically active polypeptide fusion dimers
|
AUPN154295A0
(en)
*
|
1995-03-06 |
1995-03-30 |
Commonwealth Scientific And Industrial Research Organisation |
Nucleic acid molecule encoding a protein with avian gamma-interferon activity
|
US6642032B2
(en)
|
1993-04-14 |
2003-11-04 |
Commonwealth Scientific And Industrial Research Organisation |
Uses of avian interferon gamma (IFN-γ)
|
KR100274186B1
(ko)
*
|
1993-12-22 |
2000-12-15 |
성재갑 |
싸이모신-알파와 다른 싸이토킨이 융합된 융합 단백질
|
WO1995028427A1
(en)
*
|
1994-04-15 |
1995-10-26 |
Imclone Systems Incorporated |
Chimeric interleukin-3/mutein interleukin-6 lymphokine
|
US5632983A
(en)
*
|
1994-11-17 |
1997-05-27 |
University Of South Florida |
Method for treating secondary immunodeficiency
|
US5783404A
(en)
|
1995-04-13 |
1998-07-21 |
Amgen Inc. |
Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
JPH11514217A
(ja)
|
1995-09-01 |
1999-12-07 |
コリクサ コーポレイション |
結核の診断のための化合物および方法
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
IL123506A
(en)
|
1995-09-01 |
2004-12-15 |
Corixa Corp |
Polypeptide compounds and preparations for immunotherapy and diagnosis of tuberculosis
|
US6066318A
(en)
|
1995-10-05 |
2000-05-23 |
G.D. Searle & Co. |
Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US5753243A
(en)
*
|
1996-10-31 |
1998-05-19 |
Cosmolab, Inc. |
Plasticized high water content cosmetic gel composition and pencil therefore
|
PT942740E
(pt)
|
1996-12-06 |
2004-01-30 |
Amgen Inc |
Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf
|
AU737910B2
(en)
*
|
1997-01-31 |
2001-09-06 |
Regents Of The University Of California, The |
Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
|
US6261562B1
(en)
|
1997-02-25 |
2001-07-17 |
Corixa Corporation |
Compounds for immunotherapy of prostate cancer and methods for their use
|
WO1998037093A2
(en)
|
1997-02-25 |
1998-08-27 |
Corixa Corporation |
Compounds for immunotherapy of prostate cancer and methods for their use
|
US6384203B1
(en)
|
1999-05-12 |
2002-05-07 |
Immunex Corporation |
Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
|
US6613881B1
(en)
|
1997-05-20 |
2003-09-02 |
Corixa Corporation |
Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
|
US6187564B1
(en)
|
1997-07-10 |
2001-02-13 |
Beth Israel Deaconess Medical Center |
DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
|
US6165476A
(en)
*
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
US6242570B1
(en)
|
1997-07-10 |
2001-06-05 |
Beth Israel Deaconess Medical Center |
Production and use of recombinant protein multimers with increased biological activity
|
EP1032422A4
(de)
*
|
1997-11-18 |
2003-02-05 |
Univ South Carolina |
Unterstützende einheiten linearer antigene
|
JP4336452B2
(ja)
|
1997-12-08 |
2009-09-30 |
メルク パテント ゲーエムベーハー |
標的化免疫治療および一般の免疫刺激に対して有用である二量体融合タンパク質
|
CA2316397A1
(en)
|
1997-12-24 |
1999-07-08 |
Corixa Corporation |
Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
KR20010041992A
(ko)
|
1998-03-18 |
2001-05-25 |
길리스 스티브 |
폐암의 치료와 진단을 위한 화합물 및 이를 위한 방법
|
BR9909583A
(pt)
*
|
1998-04-15 |
2002-01-15 |
Lexigen Pharm Corp |
Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese
|
US6375952B1
(en)
|
1998-08-07 |
2002-04-23 |
University Of Washington |
Immunological herpes simplex virus antigens and methods for use thereof
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
EP1121156B1
(de)
|
1998-10-16 |
2006-02-22 |
Biogen Idec MA Inc. |
Polymerkonjugate von interferon-beta-1a und deren verwendungen
|
EP1739090A3
(de)
*
|
1998-10-16 |
2009-04-08 |
Biogen Idec MA Inc. |
Interferon Beta Fusions Proteine und deren Gebrauch
|
BR9915548A
(pt)
|
1998-10-16 |
2001-08-14 |
Biogen Inc |
Proteìnas de fusão de interferon-beta e usos
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
TR200102500T2
(tr)
|
1998-12-08 |
2002-03-21 |
Corixa Corporation |
Chlamydia enfeksiyonunu tedavi etmek iin bileçikler.
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
DE60039353D1
(de)
|
1999-04-02 |
2008-08-14 |
Corixa Corp |
Verbindungen und verfahren für therapie und diagnose von lungenkrebs
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
JP2003530070A
(ja)
*
|
1999-05-19 |
2003-10-14 |
レキシジェン ファーマシューティカルズ コーポレイション |
Fc融合タンパク質としてのインターフェロン−αタンパク質の発現および搬出
|
US6319691B1
(en)
*
|
1999-06-15 |
2001-11-20 |
Usa Universe Bioengineering, Inc. |
Fusion proteins comprising IFN-alpha2b and TM-alpha1
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
BR0013231A
(pt)
*
|
1999-08-09 |
2002-07-23 |
Lexigen Pharm Corp |
Complexos citocina-anticorpo múltiplos
|
CA2386841A1
(en)
*
|
1999-10-07 |
2001-04-12 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
DE19957838C2
(de)
*
|
1999-11-25 |
2002-11-21 |
Pette Heinrich Inst |
Gentherapie von HIV-Infizierten durch Expression von Membran-verankerten gp41-Peptiden
|
NZ520171A
(en)
|
1999-12-20 |
2005-07-29 |
Immunex Corp |
Tweak receptor
|
DK1252192T3
(da)
|
2000-02-11 |
2006-11-20 |
Merck Patent Gmbh |
Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
|
AU2001241738A1
(en)
*
|
2000-02-25 |
2001-09-03 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
EP1278855B1
(de)
|
2000-04-21 |
2008-03-12 |
Corixa Corporation |
Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
|
CA2409267C
(en)
|
2000-05-26 |
2017-02-28 |
Immunex Corporation |
Interleukin-4 antagonists and compositions thereof
|
ATE526994T1
(de)
*
|
2000-06-20 |
2011-10-15 |
Corixa Corp |
Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
|
WO2002000174A2
(en)
|
2000-06-28 |
2002-01-03 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
CA2412845C
(en)
*
|
2000-06-29 |
2014-07-22 |
Lexigen Pharmaceuticals Corp. |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
IL155529A0
(en)
*
|
2000-10-30 |
2003-11-23 |
Pharmacia Corp |
Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase
|
CA2428784A1
(en)
*
|
2000-11-09 |
2002-05-16 |
Astrazeneca Ab |
Oral pharmaceutical composition containing a block copolymer
|
ZA200305980B
(en)
*
|
2001-02-12 |
2007-01-31 |
Res Dev Foundation |
Modified proteins, designer toxins, and methods of making thereof
|
MXPA03008031A
(es)
*
|
2001-03-07 |
2003-12-04 |
Merck Patent Gmbh |
Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
|
WO2002079415A2
(en)
*
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
US20030027751A1
(en)
*
|
2001-04-10 |
2003-02-06 |
Genvec, Inc. |
VEGF fusion proteins
|
BR0209177A
(pt)
*
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
JP2004535202A
(ja)
*
|
2001-07-17 |
2004-11-25 |
リサーチ ディベロップメント ファンデーション |
アポトーシス促進性蛋白質を含む治療剤
|
PL206975B1
(pl)
|
2001-12-04 |
2010-10-29 |
Merck Patent Gmbh |
Immunocytokiny o modulowanej selektywności oraz ich zastosowanie
|
AU2002365279B2
(en)
|
2001-12-17 |
2009-08-13 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
CN1639185A
(zh)
*
|
2002-01-03 |
2005-07-13 |
斯克里普斯研究学院 |
癌相关表位
|
WO2003070187A2
(en)
|
2002-02-15 |
2003-08-28 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
GB0209893D0
(en)
*
|
2002-04-30 |
2002-06-05 |
Molmed Spa |
Conjugate
|
GB0209896D0
(en)
|
2002-04-30 |
2002-06-05 |
Molmed Spa |
Conjugate
|
AU2003275985A1
(en)
*
|
2002-06-12 |
2003-12-31 |
Research Development Foundation |
Immunotoxin as a therapeutic agent and uses thereof
|
DE60335755D1
(de)
|
2002-07-18 |
2011-02-24 |
Univ Washington |
Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten
|
US20040136992A1
(en)
|
2002-08-28 |
2004-07-15 |
Burton Paul B. J. |
Compositions and method for treating cardiovascular disease
|
AU2003275449A1
(en)
*
|
2002-10-07 |
2004-05-04 |
Wei Liu |
Compositions, organisms and methodologies employing a novel human kinase
|
MXPA05003621A
(es)
*
|
2002-10-09 |
2005-10-19 |
Rinat Neuroscience Corp |
Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
|
WO2004032877A2
(en)
*
|
2002-10-10 |
2004-04-22 |
Wyeth |
Compositions, organisms and methodologies employing a novel human kinase
|
BR0314614A
(pt)
*
|
2002-10-10 |
2005-07-26 |
Wyeth Corp |
Composições, organismos e metologias empregando uma nova cinase humana
|
WO2004036221A2
(en)
*
|
2002-10-18 |
2004-04-29 |
Wyeth |
Compositions and methods for diagnosing and treating autoimmune disease
|
CA2503491A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Wyeth |
Calcineurin-like human phosphoesterase
|
BR0316111A
(pt)
*
|
2002-11-21 |
2005-09-13 |
Wyeth Corp |
Métodos para diagnosticar rcc e outros tumores sólidos
|
AU2003290664A1
(en)
*
|
2002-11-27 |
2004-06-23 |
Wei Liu |
Compositions, organisms and methodologies employing a novel human kinase
|
MXPA05006384A
(es)
*
|
2002-12-17 |
2005-08-29 |
Merck Patent Gmbh |
Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
|
CA2511907A1
(en)
|
2003-01-06 |
2004-07-22 |
Wyeth |
Compositions and methods for diagnosing and treating colon cancers
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
EP1589934B1
(de)
|
2003-01-06 |
2015-09-23 |
Corixa Corporation |
Bestimmte aminoalkyl-glucosaminid-phosphatverbindungen und ihre verwendung
|
US20040191818A1
(en)
*
|
2003-02-26 |
2004-09-30 |
O'toole Margot Mary |
Compositions and methods for diagnosing and treating autoimmune diseases
|
RU2005130636A
(ru)
*
|
2003-03-04 |
2006-05-10 |
Уайт (Us) |
Композиции и способы диагностики и лечения астмы или других аллергических или воспалительных заболеваний
|
EP2463299A3
(de)
|
2003-03-05 |
2012-10-17 |
Dendreon Corporation |
Zusammensetzungen und Verfahren unter Anwendung von Polypeptiden mit alternativem Leserahmen zur Behandlung von Krebs und Infektionskrankheiten
|
US20050119210A1
(en)
*
|
2003-05-20 |
2005-06-02 |
Xiaobing Be |
Compositions and methods for diagnosing and treating cancers
|
DE602004031341D1
(de)
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
DE602004031681D1
(de)
|
2003-07-21 |
2011-04-14 |
Transgene Sa |
Multifunktionelle Cytokine
|
ATE554108T1
(de)
|
2003-07-25 |
2012-05-15 |
Amgen Inc |
Verfahren bezüglich ldcam und crtam
|
US20050069521A1
(en)
*
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
WO2005052129A2
(en)
|
2003-11-25 |
2005-06-09 |
Anjin Corporation |
Diptheria toxin variant
|
US7576183B2
(en)
*
|
2003-12-24 |
2009-08-18 |
Los Alamos National Security, Llc |
Structure-based receptor MIMICS targeted against bacterial superantigen toxins
|
ATE393169T1
(de)
*
|
2003-12-30 |
2008-05-15 |
Merck Patent Gmbh |
Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
|
EP1699821B1
(de)
*
|
2003-12-31 |
2012-06-20 |
Merck Patent GmbH |
Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MIT VERBESSERTER PHARMAKOKINETIK
|
PL1706428T3
(pl)
*
|
2004-01-22 |
2010-02-26 |
Merck Patent Gmbh |
Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
|
US20050201995A1
(en)
*
|
2004-02-05 |
2005-09-15 |
Board Of Regents, The University Of Texas System |
Methods and compositions related to neuronal differentiation
|
US7798041B2
(en)
*
|
2004-04-15 |
2010-09-21 |
Milwaukee Electric Tool Corporation |
Miter adjustment assembly for a saw
|
AU2005285513B2
(en)
|
2004-05-25 |
2011-02-24 |
Oregon Health And Science University |
SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
|
EP2199801B1
(de)
|
2004-07-14 |
2013-05-29 |
The Regents of The University of California |
Biomarker zur Früherkennung von Eierstockkrebs
|
KR101068289B1
(ko)
*
|
2004-07-30 |
2011-09-28 |
리나트 뉴로사이언스 코퍼레이션 |
아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법
|
CA2574881C
(en)
|
2004-08-04 |
2013-01-08 |
Amgen Inc. |
Antibodies to dkk-1
|
US8697139B2
(en)
|
2004-09-21 |
2014-04-15 |
Frank M. Phillips |
Method of intervertebral disc treatment using articular chondrocyte cells
|
JP4937132B2
(ja)
*
|
2004-12-09 |
2012-05-23 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
免疫原性の低下したil−7変種
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
CA2595904A1
(en)
*
|
2005-02-01 |
2006-08-10 |
Research Development Foundation |
Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders
|
EP1701165A1
(de)
|
2005-03-07 |
2006-09-13 |
Johannes Dr. Coy |
Therapeutischer und diagnostischer Gebrauch von TKTL1 sowie seiner Inhibitoren und Aktivatoren
|
EP2392349A3
(de)
|
2005-03-31 |
2012-01-18 |
GlaxoSmithKline Biologicals S.A. |
Impfstoffe gegen Chlamydieninfektion
|
PE20061323A1
(es)
*
|
2005-04-29 |
2007-02-09 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
|
KR20120089475A
(ko)
|
2005-04-29 |
2012-08-10 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
|
US8227573B2
(en)
*
|
2005-05-20 |
2012-07-24 |
University Of Kentucky Research Foundation |
Utility of phylloplanins as antibiotics, selective fungicides and for enhancing microbial resistance in plants
|
US7528232B2
(en)
*
|
2005-05-20 |
2009-05-05 |
The University Of Kentucky Research Foundation |
Utility of phylloplanins as antibiotics, selective fungicides and for enhancing microbial resistance in crop plants
|
BRPI0613168A2
(pt)
|
2005-07-01 |
2010-12-21 |
Forsyth Dental In Ry For Children Fa |
molécula de polipeptìdeo isolada; molécula de ácido nucléico isolada; vetor ou plasmìdeo; célula hospedeira; anticorpo; proteìna de fusão; método para estimular uma resposta imunogênica especìfica à tb em um indivìduo ou para prevenir ou reduzir a gravidade de doença causada pela tb; método para monitorar o tratamento da doença causada pela tb em um indivìduo; método de diagnóstico de doença causada pela tb em um indivìduo; método de distinção entre a doença causada pela tb e a imunidade à doença causada pela tb em um indivìduo; método para detecção da infecção por m. tuberculosis em uma amostra biológica; composição; kit para diagnóstico da presença ou da ausência de infecção por m. tuberculosis em uma pessoa; e composição farmacêutica
|
US7494788B2
(en)
*
|
2005-07-11 |
2009-02-24 |
Molecular Kinetics, Inc. |
Entropic bristle domain sequences and their use in recombinant protein production
|
KR100755676B1
(ko)
*
|
2005-08-26 |
2007-09-05 |
삼성전자주식회사 |
밝기 향상 및 전력 제어를 지원하는 영상 표시 장치 및방법
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
KR20080082629A
(ko)
*
|
2005-11-10 |
2008-09-11 |
리셉터 바이오로직스 인크 |
간세포 성장인자 인트론 융합 단백질
|
EP1966238B1
(de)
*
|
2005-12-30 |
2012-04-25 |
Merck Patent GmbH |
Interleukin-12p40-varianten mit verbesserter stabilität
|
WO2007076950A1
(en)
|
2005-12-30 |
2007-07-12 |
Merck Patent Gmbh |
Anti-cd19 antibodies with reduced immunogenicity
|
WO2007120368A2
(en)
|
2006-01-09 |
2007-10-25 |
The Regents Of The University Of California |
Immunostimulatory combinations for vaccine adjuvants
|
EP1981905B1
(de)
|
2006-01-16 |
2016-08-31 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Chlamydia-impfstoff
|
US8129334B2
(en)
|
2006-03-31 |
2012-03-06 |
The Regents Of The University Of California |
Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
|
US8569015B2
(en)
*
|
2006-05-30 |
2013-10-29 |
Pfenex Inc. |
RPA optimization
|
US20070292918A1
(en)
*
|
2006-05-30 |
2007-12-20 |
Stelman Steven J |
Codon optimization method
|
EP2044115A2
(de)
*
|
2006-06-12 |
2009-04-08 |
Receptor Biologix, Inc. |
Für die oberflächenrezeptoren von pan-zellen spezifische therapeutika
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
MX341064B
(es)
|
2006-09-08 |
2016-08-05 |
Amgen Inc * |
Variantes de la familia il-1.
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
EP2080012B1
(de)
*
|
2006-11-10 |
2013-03-20 |
Dimerix Bioscience Pty.Ltd. |
Verfahren zur Untersuchung von Testsubstanzen an assoziierten Rezeptoren
|
MX351247B
(es)
|
2007-04-04 |
2017-10-05 |
Infectious Disease Res Institute Star |
Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
|
EP2167528B1
(de)
|
2007-06-21 |
2018-01-10 |
Angelica Therapeutics, INC. |
Modifizierte toxine
|
CL2008001887A1
(es)
|
2007-06-29 |
2008-10-03 |
Amgen Inc |
Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
|
EP2188313B1
(de)
|
2007-08-21 |
2017-11-01 |
Amgen, Inc. |
An menschliches c-fms bindende antigenbindende proteine
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
WO2009052184A2
(en)
*
|
2007-10-16 |
2009-04-23 |
Receptor Biologix, Inc. |
Compositions comprising optimized her1 and her3 multimers and methods of use thereof
|
EP2220247A4
(de)
|
2007-11-16 |
2011-10-26 |
Nuvelo Inc |
Antikörper gegen lrp6
|
US8470314B2
(en)
*
|
2008-02-29 |
2013-06-25 |
Angelica Therapeutics, Inc. |
Modified toxins
|
US8404471B2
(en)
|
2008-06-26 |
2013-03-26 |
Atyr Pharma, Inc. |
Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities
|
AU2009262199B2
(en)
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
EA027693B1
(ru)
|
2008-09-26 |
2017-08-31 |
Токаджен Инк. |
Рекомбинантный репликационно-компетентный ретровирус с цитозиндезаминазной активностью для генной терапии нарушений клеточной пролиферации
|
US10131693B2
(en)
|
2008-10-20 |
2018-11-20 |
Gwangju Institute Of Science And Technology |
Bipodal-peptide binder
|
EP2356146A1
(de)
|
2008-11-07 |
2011-08-17 |
Fabrus Llc |
Anti-dll4-antikörper und anwendungen davon
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
US8835137B2
(en)
|
2008-12-23 |
2014-09-16 |
Matrix Genetics, Llc |
Modified photosynthetic microorganisms with reduced glycogen and their use in producing carbon-based products
|
WO2010080910A1
(en)
|
2009-01-08 |
2010-07-15 |
Bio-Rad Laboratories, Inc. |
Methods and compositions for improving efficiency of nucleic acids amplification reactions
|
ES2552773T3
(es)
|
2009-02-27 |
2015-12-02 |
Atyr Pharma, Inc. |
Motivos estructurales de polipéptidos asociados con la actividad de señalización celular
|
CN104830812B
(zh)
|
2009-03-16 |
2017-09-05 |
盘古生物制药有限公司 |
包含具有非经典生物活性的组氨酰‑tRNA合成酶剪接变异体的组合物及方法
|
MX338969B
(es)
|
2009-03-20 |
2016-05-06 |
Amgen Inc |
Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
|
JP5848236B2
(ja)
|
2009-03-31 |
2016-01-27 |
エータイアー ファーマ, インコーポレイテッド |
非標準的な生物活性を有するアスパルチルtRNA合成酵素を含む組成物および方法
|
CN107243076A
(zh)
|
2009-04-22 |
2017-10-13 |
印第安那大学科技研究公司 |
用于治疗慢性阻塞性肺病和哮喘的组合物和方法
|
CN102459576B
(zh)
|
2009-04-27 |
2015-04-01 |
渥太华医院研究所 |
用于调节干细胞的组合物和方法及其应用
|
JP2012533587A
(ja)
|
2009-07-22 |
2012-12-27 |
セニックス バイオサイエンス ゲーエムベーハー |
自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート
|
WO2011014671A1
(en)
|
2009-07-31 |
2011-02-03 |
Amgen Inc. |
Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
|
MX2012001882A
(es)
*
|
2009-08-13 |
2012-04-11 |
Crucell Holland Bv |
Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
WO2011072266A2
(en)
|
2009-12-11 |
2011-06-16 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating hematopoiesis
|
DK2509625T3
(en)
|
2009-12-11 |
2015-04-27 |
Atyr Pharma Inc |
Histidyl tRNA synthetases to reduce inflammation
|
UA110103C2
(uk)
|
2010-01-27 |
2015-11-25 |
Ґлаксосмітклайн Байолоджікалз С.А. |
Модифікований туберкульозний антиген
|
US8846603B2
(en)
|
2010-03-12 |
2014-09-30 |
Synageva Biopharma Corp. |
NPP1 fusion proteins
|
WO2011127069A1
(en)
|
2010-04-06 |
2011-10-13 |
Targeted Growth, Inc. |
Modified photosynthetic microorganisms for producing lipids
|
JP2013528360A
(ja)
|
2010-04-09 |
2013-07-11 |
アムジェン インコーポレイテッド |
Btnl9タンパク質、核酸および抗体ならびにそれらの使用
|
AU2011239689A1
(en)
|
2010-04-15 |
2012-11-08 |
Amgen Inc. |
Human FGF receptor and beta-Klotho binding proteins
|
NZ603488A
(en)
|
2010-07-09 |
2015-02-27 |
Crucell Holland Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
EA201390242A1
(ru)
|
2010-08-16 |
2013-07-30 |
Амген Инк. |
Антитела, связывающие миостатин, композиции и способы
|
WO2012034039A2
(en)
|
2010-09-10 |
2012-03-15 |
Apexigen, Inc. |
Anti-il-1 beta antibodies and methods of use
|
EP3219725B1
(de)
|
2010-10-27 |
2020-12-16 |
Amgen Inc. |
Dkk1-antikörper-zusammensetzungen und verfahren zur verwendung
|
US20130345079A1
(en)
|
2010-10-27 |
2013-12-26 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
WO2012064659A1
(en)
|
2010-11-08 |
2012-05-18 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
EP2655605A1
(de)
|
2010-12-20 |
2013-10-30 |
Matrix Genetics, LLC |
Modifizierte fotosynthetische mikroorganismen zur herstellung von lipiden
|
WO2012087982A2
(en)
|
2010-12-20 |
2012-06-28 |
Targeted Growth, Inc. |
Modified photosynthetic microorganisms for producing lipids
|
JP6087836B2
(ja)
|
2011-01-11 |
2017-03-01 |
ディメリックス バイオサイエンス プロプライアタリー リミテッド |
併用療法
|
CA2824235A1
(en)
|
2011-01-11 |
2012-07-19 |
Fate Therapeutics, Inc. |
Novel wnt compositions and therapeutic uses of such compositions
|
CA2825023A1
(en)
|
2011-01-26 |
2012-08-02 |
Cenix Bioscience Gmbh |
Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
|
CA2825894C
(en)
|
2011-02-02 |
2021-11-30 |
Amgen Inc. |
Prognosis of cancer using a circulating biomarker
|
EP2681242B1
(de)
|
2011-03-01 |
2018-01-24 |
Amgen Inc. |
Sclerostin- und dkk-1-bispezifische bindemittel
|
EP2681243B1
(de)
|
2011-03-03 |
2018-09-05 |
Apexigen, Inc. |
Anti-il-6-rezeptor-antikörper und verfahren zu ihrer verwendung
|
SG193024A1
(en)
|
2011-03-11 |
2013-10-30 |
Synageva Biopharma Corp |
Npp1 fusion proteins
|
US8916352B2
(en)
|
2011-04-08 |
2014-12-23 |
Bio-Rad Laboratories, Inc. |
PCR reaction mixtures with decreased non-specific activity
|
ES2709654T3
(es)
|
2011-04-29 |
2019-04-17 |
Apexigen Inc |
Anticuerpos anti-CD40 y métodos de uso
|
CN107936121B
(zh)
|
2011-05-16 |
2022-01-14 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
DK3564378T3
(da)
|
2011-05-27 |
2024-01-08 |
Glaxosmithkline Biologicals Sa |
Immunogen sammensætning
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
US8470573B2
(en)
|
2011-06-21 |
2013-06-25 |
Bio-Rad Laboratories, Inc. |
Hybrid polymerases having the ability to produce long amplicons
|
AU2012273153A1
(en)
|
2011-06-21 |
2013-05-02 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
WO2013006706A1
(en)
|
2011-07-05 |
2013-01-10 |
Bioasis Technologies Inc. |
P97-antibody conjugates and methods of use
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
WO2013033260A1
(en)
|
2011-08-29 |
2013-03-07 |
The Regents Of The University Of California |
Use of hdl-related molecules to treat and prevent proinflammatory conditions
|
CN103998462A
(zh)
|
2011-09-16 |
2014-08-20 |
菲特治疗公司 |
Wnt组合物及此类组合物的治疗应用
|
EP2751257B1
(de)
|
2011-09-16 |
2018-06-27 |
Ottawa Hospital Research Institute |
Wnt7a-zusammensetzungen und verfahren zu ihrer verwendung
|
JO3625B1
(ar)
|
2011-09-22 |
2020-08-27 |
Amgen Inc |
بروتينات رابطة للأنتيجين cd27l
|
SG11201401797TA
(en)
|
2011-10-24 |
2014-09-26 |
Halozyme Inc |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
US9441042B2
(en)
|
2011-11-02 |
2016-09-13 |
Apexigen, Inc. |
Anti-KDR antibodies and methods of use
|
EP2788384B1
(de)
|
2011-12-08 |
2017-08-09 |
Amgen Inc. |
Agonistische menschliche lcat-antigenbindende proteine und ihre verwendung in der therapie
|
CA2864177C
(en)
|
2012-03-01 |
2019-11-26 |
Amgen Research (Munich) Gmbh |
Prolonged half-life albumin-binding protein fused bispecific antibodies
|
US20130236484A1
(en)
|
2012-03-08 |
2013-09-12 |
Detectogen Inc. |
Leishmaniasis antigen detection assays and vaccines
|
SG11201405553YA
(en)
|
2012-03-08 |
2014-11-27 |
Halozyme Inc |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
EP2834868B1
(de)
|
2012-04-02 |
2023-12-27 |
Hydrogenics Corporation |
Brennstoffzellenstartverfahren
|
KR102213694B1
(ko)
|
2012-04-27 |
2021-02-09 |
노보 노르디스크 에이/에스 |
사람 cd30 리간드 항원 결합 단백질
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
EP2847219A1
(de)
|
2012-05-07 |
2015-03-18 |
Amgen Inc. |
Anti-erythropoietin-antikörper
|
PL2863942T3
(pl)
|
2012-06-21 |
2019-12-31 |
Northwestern University |
Cząstki sprzężone z peptydem
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
CA2878400A1
(en)
|
2012-07-19 |
2014-01-23 |
Amgen Inc. |
Btnl3 proteins, nucleic acids, and antibodies and uses thereof
|
US9962436B2
(en)
|
2012-07-26 |
2018-05-08 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Multimeric fusion protein vaccine and immunotherapeutic
|
ES2647082T3
(es)
|
2012-07-31 |
2017-12-19 |
Bioasis Technologies Inc |
Proteínas desfosforiladas de la enfermedad de depósito lisosómico y métodos de uso de las mismas
|
HRP20240164T1
(hr)
|
2012-08-03 |
2024-04-12 |
Access To Advanced Health Institute |
Pripravci i postupci za liječenje aktivne tuberkulozne infekcije mikobakterijama
|
WO2014031575A1
(en)
|
2012-08-20 |
2014-02-27 |
The Regents Of The University Of California |
Polynucleotides having bioreversible groups
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
CN104918957B
(zh)
|
2012-10-30 |
2018-11-16 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
JP6290918B2
(ja)
|
2012-12-05 |
2018-03-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
WO2014114801A1
(en)
|
2013-01-25 |
2014-07-31 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
MX2015009901A
(es)
|
2013-02-01 |
2016-04-06 |
Santa Maria Biotherapeutics Inc |
Administración de un compuesto de antiactivina a a un sujeto.
|
US9914907B2
(en)
|
2013-03-13 |
2018-03-13 |
Lumen Bioscience, Inc. |
Cyanobacteria having improved photosynthetic activity
|
WO2014164232A1
(en)
|
2013-03-13 |
2014-10-09 |
Matrix Genetics, Llc |
Cyanobacteria that produce lipid packaging proteins
|
JP6586412B2
(ja)
|
2013-03-13 |
2019-10-02 |
バイオアシス テクノロジーズ インコーポレイテッド |
p97のフラグメントおよびその使用
|
EP2970451A1
(de)
|
2013-03-14 |
2016-01-20 |
Amgen Inc. |
Chrdl-1-antigenbindende proteine und behandlungsmethoden damit
|
US9850297B2
(en)
|
2013-03-15 |
2017-12-26 |
Amgen Inc. |
Secreted frizzle-related protein 5 (SFRP5) binding proteins
|
CA2902905A1
(en)
|
2013-03-15 |
2014-09-25 |
Claude Geoffrey Davis |
Modified toxins
|
AU2014228924B2
(en)
|
2013-03-15 |
2019-04-18 |
Amgen Inc. |
Human PAC1 antibodies
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
CN114717206A
(zh)
|
2013-03-15 |
2022-07-08 |
Atyr 医药公司 |
组氨酰-trna合成酶-fc缀合物
|
AU2014236867A1
(en)
|
2013-03-15 |
2015-09-24 |
Amgen Inc. |
Methods and compositions relating to anti-CCR7 antigen binding proteins
|
NZ629682A
(en)
|
2013-03-15 |
2017-03-31 |
Omeros Corp |
Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
|
WO2014140358A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Single chain binding molecules comprising n-terminal abp
|
US20140363433A1
(en)
|
2013-03-15 |
2014-12-11 |
Omeros Corporation |
Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
|
ES2728865T3
(es)
|
2013-03-28 |
2019-10-29 |
Infectious Disease Res Inst |
Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
|
ES2762187T3
(es)
|
2013-08-13 |
2020-05-22 |
Univ Northwestern |
Partículas conjugadas con péptidos
|
WO2015031673A2
(en)
|
2013-08-28 |
2015-03-05 |
Bioasis Technologies Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
BR112016005526A2
(pt)
|
2013-09-12 |
2017-09-12 |
Halozyme Inc |
anticorpos receptores de fator de crescimento anti-epidérmido modificado e métodos de uso dos mesmos
|
AR097648A1
(es)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
US9840697B2
(en)
|
2013-12-06 |
2017-12-12 |
Bio-Rad Laboratories, Inc. |
Fusion polymerases
|
CN106456724A
(zh)
|
2013-12-20 |
2017-02-22 |
博德研究所 |
使用新抗原疫苗的联合疗法
|
AU2015274238B2
(en)
|
2014-06-13 |
2020-11-05 |
Csl Limited |
Improved production of recombinant von Willebrand factor in a bioreactor
|
EP3636278A3
(de)
|
2014-06-25 |
2020-07-15 |
GlaxoSmithKline Biologicals S.A. |
Clostridium difficile immunogene zusammensetzung
|
EP3172332B1
(de)
|
2014-07-22 |
2020-10-14 |
Bio-rad Laboratories, Inc. |
Puffer zur verwendung mit polymerasen
|
TW201609811A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
具有增強之組織分布之雙特異性單鏈抗體構築體
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
AR101936A1
(es)
|
2014-07-31 |
2017-01-25 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
JP2017529078A
(ja)
|
2014-09-15 |
2017-10-05 |
リライアンス ホールディング ユーエスエー, インコーポレイテッド |
光合成の活動を改善している藍藻(シアノバクテリア)
|
CA3126536C
(en)
|
2014-10-14 |
2023-07-25 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
CN111018987B
(zh)
|
2014-12-05 |
2023-11-21 |
鸿运华宁(杭州)生物医药有限公司 |
一种能与人内皮素受体特异性结合的抗体及其应用
|
AU2015364411A1
(en)
|
2014-12-19 |
2017-06-08 |
Alexion Pharmaceuticals, Inc. |
Methods of treating tissue calcification
|
WO2016100977A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Methods for profiling the t-cel- receptor repertoire
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
KR102435383B1
(ko)
|
2015-01-16 |
2022-08-24 |
미노믹 인터내셔널 리미티드 |
글리피칸 에피토프 및 이의 용도
|
ES2945313T3
(es)
|
2015-04-17 |
2023-06-30 |
Amgen Res Munich Gmbh |
Construcciones de anticuerpos biespecificos para CDH3 y CD3
|
WO2016184784A1
(en)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1
|
EP3297660A2
(de)
|
2015-05-20 |
2018-03-28 |
The Broad Institute Inc. |
Gemeinsam genutzte neoantigene
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
EP3356415B1
(de)
|
2015-09-29 |
2024-05-01 |
Amgen Inc. |
Asgr-inhibitoren
|
US10364420B2
(en)
|
2015-12-07 |
2019-07-30 |
Bio-Rad Laboratories, Inc |
Dimeric reverse transcriptase
|
EP3393514A4
(de)
|
2015-12-23 |
2019-08-14 |
Cour Pharmaceuticals Development Company Inc. |
Kovalente polymer-antigen-konjugierte partikel
|
TWI797073B
(zh)
|
2016-01-25 |
2023-04-01 |
德商安美基研究(慕尼黑)公司 |
包含雙特異性抗體建構物之醫藥組合物
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
EA201891753A1
(ru)
|
2016-02-03 |
2019-01-31 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
|
UA126657C2
(uk)
|
2016-02-03 |
2023-01-11 |
Емджен Рісерч (Мюнік) Ґмбг |
ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
|
US10870701B2
(en)
|
2016-03-15 |
2020-12-22 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
JP2019521095A
(ja)
|
2016-05-21 |
2019-07-25 |
インフェクシャス ディズィーズ リサーチ インスティチュート |
二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
|
TWI826351B
(zh)
|
2016-05-31 |
2023-12-21 |
大陸商鴻運華寧(杭州)生物醫藥有限公司 |
R抗體,其藥物組合物及其應用
|
EP3827835A1
(de)
|
2016-06-16 |
2021-06-02 |
Inozyme Pharma, Inc. |
Verfahren zur behandlung von myointimaler proliferation
|
AU2017302611B2
(en)
|
2016-07-28 |
2021-12-09 |
Regeneron Pharmaceuticals, Inc. |
GPR156 variants and uses thereof
|
TWI765900B
(zh)
|
2016-08-03 |
2022-06-01 |
中國大陸商軒竹(北京)醫藥科技有限公司 |
哌唑黴素(plazomicin)抗體及使用方法
|
US20190309274A1
(en)
|
2016-08-16 |
2019-10-10 |
Bluebird Bio, Inc. |
Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
|
JP2019532027A
(ja)
|
2016-08-17 |
2019-11-07 |
ソルスティス バイオロジクス,リミティッド |
ポリヌクレオチド構築物
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
WO2018039333A1
(en)
|
2016-08-23 |
2018-03-01 |
Bluebird Bio, Inc. |
Tim3 homing endonuclease variants, compositions, and methods of use
|
KR102622910B1
(ko)
|
2016-09-08 |
2024-01-10 |
2세븐티 바이오, 인코포레이티드 |
Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법
|
BR112019004913B1
(pt)
|
2016-09-16 |
2022-07-12 |
Infectious Disease Research Institute |
Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
CA3040157A1
(en)
|
2016-10-17 |
2018-04-26 |
Bluebird Bio, Inc. |
Tgf.beta.r2 endonuclease variants, compositions, and methods of use
|
MX2019005724A
(es)
|
2016-11-17 |
2019-07-08 |
Bluebird Bio Inc |
Conversor de se?ales de tgfbeta.
|
KR20190111067A
(ko)
|
2017-01-23 |
2019-10-01 |
리제너론 파마슈티칼스 인코포레이티드 |
하이드록시스테로이드 17-베타 탈수소효소 13 (hsd17b13) 변이체 및 이의 용도
|
EP3574116A1
(de)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
SI3580561T1
(sl)
|
2017-02-12 |
2024-04-30 |
Biontech Us Inc. |
Metode, osnovane na hla, in njihove sestave ter uporabe
|
EP3583203B1
(de)
|
2017-02-15 |
2023-11-01 |
2seventy bio, Inc. |
Spenderreparaturtemplates für multiplex-genomeditierung
|
WO2018152097A1
(en)
|
2017-02-16 |
2018-08-23 |
Bio-Rad Laboratories, Inc. |
Novel reverse transcriptases and uses thereof
|
EP3612215A4
(de)
|
2017-04-20 |
2021-05-26 |
aTyr Pharma, Inc. |
Zusammensetzungen und verfahren zur behandlung von lungenentzündungen
|
BR112019022751A2
(pt)
|
2017-05-05 |
2020-05-19 |
Amgen Inc |
composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados
|
AU2018270088B2
(en)
|
2017-05-18 |
2024-05-16 |
Massachusetts Institute Of Technology |
Systems, methods, and compositions for targeted nucleic acid editing
|
WO2018218194A1
(en)
|
2017-05-25 |
2018-11-29 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
CA3065938A1
(en)
|
2017-06-05 |
2018-12-13 |
Regeneron Pharmaceuticals, Inc. |
B4galt1 variants and uses thereof
|
JP7454494B2
(ja)
|
2017-06-26 |
2024-03-22 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
標的化された核酸編集のためのcrispr/cas-アデニンデアミナーゼ系の組成物、系及び方法
|
US11597744B2
(en)
|
2017-06-30 |
2023-03-07 |
Sirius Therapeutics, Inc. |
Chiral phosphoramidite auxiliaries and methods of their use
|
CA3072003A1
(en)
|
2017-08-23 |
2019-02-28 |
Csl Behring Gmbh |
Method for virus filtration of von willebrand factor
|
CN111373053A
(zh)
|
2017-09-06 |
2020-07-03 |
雷杰纳荣制药公司 |
单免疫球蛋白白介素-1受体相关分子(sigirr)变体及其用途
|
CN111278851A
(zh)
|
2017-09-07 |
2020-06-12 |
雷杰纳荣制药公司 |
溶质运载体家族14成员1(slc14a1)变体及其用途
|
CA3072600A1
(en)
|
2017-09-15 |
2019-03-21 |
Amgen Inc. |
Process for lyophilized pharmaceutical formulation of a therapeutic protein
|
WO2019060115A1
(en)
|
2017-09-19 |
2019-03-28 |
Advaxis, Inc. |
COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS
|
CA3073848A1
(en)
|
2017-09-21 |
2019-03-28 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
JP2020535161A
(ja)
|
2017-09-27 |
2020-12-03 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。
|
EP3461497A1
(de)
|
2017-09-27 |
2019-04-03 |
GlaxoSmithKline Biologicals S.A. |
Virale antigene
|
JP2020536552A
(ja)
|
2017-10-10 |
2020-12-17 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ctla−4変異型免疫調節タンパク質およびそれらの使用
|
SG11202002822XA
(en)
|
2017-10-16 |
2020-04-29 |
Regeneron Pharma |
Cornulin (crnn) variants and uses thereof
|
US11292846B2
(en)
|
2017-11-02 |
2022-04-05 |
Bayer Aktiengesellschaft |
Bispecific antibodies binding ALK-1 and BMPR-2
|
BR112020011627A2
(pt)
|
2017-12-11 |
2020-11-17 |
Amgen Inc. |
processo de fabricação contínuo para produtos de anticorpos biespecíficos
|
EP3723787A4
(de)
|
2017-12-14 |
2021-09-01 |
Bluebird Bio, Inc. |
Daric-interleukinrezeptoren
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
US20230101432A1
(en)
|
2018-01-03 |
2023-03-30 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
CA3091352A1
(en)
|
2018-02-21 |
2019-08-29 |
The University Of Montana |
Diaryl trehalose compounds and uses thereof
|
US11572381B2
(en)
|
2018-03-02 |
2023-02-07 |
The University Of Montana |
Immunogenic trehalose compounds and uses thereof
|
CA3093467C
(en)
|
2018-03-09 |
2022-12-06 |
Advaxis, Inc. |
Compositions and methods for evaluating attenuation and infectivity of listeria strains
|
CN117126279A
(zh)
|
2018-03-20 |
2023-11-28 |
鸿运华宁(杭州)生物医药有限公司 |
Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
|
CN110357959B
(zh)
|
2018-04-10 |
2023-02-28 |
鸿运华宁(杭州)生物医药有限公司 |
Gcgr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
|
US20210239681A1
(en)
|
2018-04-27 |
2021-08-05 |
Advaxis, Inc. |
Compositions and methods for evaluating potency of listeria-based immunotherapeutics
|
KR102167755B1
(ko)
|
2018-05-23 |
2020-10-19 |
주식회사 큐어바이오 |
단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
|
WO2019232246A1
(en)
|
2018-05-31 |
2019-12-05 |
Glyconex Inc. |
Therapeutic antibodies binding to biantennary lewis b and lewis y antigens
|
CN110655577A
(zh)
|
2018-06-13 |
2020-01-07 |
鸿运华宁(杭州)生物医药有限公司 |
APJ抗体及其与Elabela的融合蛋白质,以及其药物组合物和应用
|
EP3813867A1
(de)
|
2018-07-22 |
2021-05-05 |
Bioasis Technologies Inc. |
Behandlung von lymphatischen metastasen
|
MA53325A
(fr)
|
2018-07-30 |
2021-06-09 |
Amgen Inc |
Administration prolongée d'une construction d'anticorps bispécifique se liant à cd33 et cd3
|
SG11202102068TA
(en)
|
2018-07-31 |
2021-03-30 |
Broad Inst Inc |
Novel crispr enzymes and systems
|
EP3829633A1
(de)
|
2018-08-03 |
2021-06-09 |
Amgen Research (Munich) GmbH |
Antikörperkonstrukte für cldn18.2 und cd3
|
CA3106035A1
(en)
|
2018-08-07 |
2020-02-13 |
The Broad Institute, Inc. |
Cas12b enzymes and systems
|
TW202028239A
(zh)
|
2018-09-28 |
2020-08-01 |
美商安進公司 |
針對可溶性bcma之抗體
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
WO2020072059A1
(en)
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
EP3863670A1
(de)
|
2018-10-11 |
2021-08-18 |
Amgen Inc. |
Downstream-verarbeitung von bispezifischen antikörperkonstrukten
|
CA3124110A1
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
CA3124457A1
(en)
|
2018-12-21 |
2020-06-25 |
Biontech Us Inc. |
Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
JP2022516725A
(ja)
|
2018-12-28 |
2022-03-02 |
カタリスト・バイオサイエンシーズ・インコーポレイテッド |
改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法
|
US20220137010A1
(en)
|
2019-02-20 |
2022-05-05 |
Amgen Inc. |
Methods of determining protein stability
|
WO2020193520A1
(en)
|
2019-03-25 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Treatment of taupathy disorders by targeting new tau species
|
CA3133459A1
(en)
|
2019-03-27 |
2020-10-01 |
Amgen Inc. |
Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
CA3137494A1
(en)
|
2019-06-13 |
2020-12-17 |
Amgen Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
CN112239507A
(zh)
|
2019-07-17 |
2021-01-19 |
鸿运华宁(杭州)生物医药有限公司 |
ETA抗体与TGF-β Trap的融合蛋白质,以及其药物组合物和应用
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
AU2020345787A1
(en)
|
2019-09-10 |
2022-03-24 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
|
CN112521501A
(zh)
|
2019-09-18 |
2021-03-19 |
鸿运华宁(杭州)生物医药有限公司 |
Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
|
EP4031660A1
(de)
|
2019-09-20 |
2022-07-27 |
The Broad Institute, Inc. |
Neuartige typ-vi-crispr-enzyme und systeme
|
CA3156683A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
|
WO2021140209A1
(en)
|
2020-01-10 |
2021-07-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Rspo1 proteins and their use
|
US20230093169A1
(en)
|
2020-01-22 |
2023-03-23 |
Amgen Research (Munch) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
CN115697388A
(zh)
|
2020-01-30 |
2023-02-03 |
优莫佳生物制药股份有限公司 |
双特异性转导增强子
|
MA56074B1
(fr)
|
2020-02-26 |
2023-11-30 |
Vir Biotechnology Inc |
Anticorps contre le sars-cov-2
|
EP4118113A1
(de)
|
2020-03-12 |
2023-01-18 |
Amgen Inc. |
Verfahren zur behandlung und prophylaxe von crs bei patienten mit einer kombination aus bispezifischen antikörpern zur bindung an cds x-krebszellen und tnfalpha- oder il-6-hemmer
|
BR112022018111A2
(pt)
|
2020-03-19 |
2022-10-25 |
Amgen Inc |
Anticorpos contra mucina 17 e usos dos mesmos
|
WO2021203053A1
(en)
|
2020-04-03 |
2021-10-07 |
Vir Biotechnology, Inc. |
Immunotherapy targeting a conserved region in sars coronaviruses
|
EP4135846A1
(de)
|
2020-04-14 |
2023-02-22 |
VIR Biotechnology, Inc. |
Antikörper gegen sars-cov-2 und verfahren zu ihrer verwendung
|
KR20230004798A
(ko)
|
2020-04-29 |
2023-01-06 |
암젠 인크 |
제약 제형
|
KR20230004799A
(ko)
|
2020-04-29 |
2023-01-06 |
암젠 인크 |
제약 제형
|
EP4146695A1
(de)
|
2020-05-04 |
2023-03-15 |
Immunorizon Ltd. |
Vorläufertrispezifische antikörperkonstrukte und verfahren zur verwendung davon
|
IL297988A
(en)
|
2020-05-08 |
2023-01-01 |
Vir Biotechnology Inc |
Antibodies against sars-cov-2
|
EP4146684A2
(de)
|
2020-05-08 |
2023-03-15 |
Alpine Immune Sciences, Inc. |
April- und baff-hemmende immunmodulatorische proteine mit und ohne t-zell-hemmendes protein und verfahren zur verwendung davon
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
CA3183756A1
(en)
|
2020-05-19 |
2021-11-25 |
Amgen Inc. |
Mageb2 binding constructs
|
EP4157874A2
(de)
|
2020-05-29 |
2023-04-05 |
Amgen Inc. |
Die nebenwirkungen mindernde verabreichung eines bispezifischen antikörperkonstrukts, das an cd33 und cd3 bindet
|
WO2021247925A1
(en)
|
2020-06-03 |
2021-12-09 |
Vir Biotechnology, Inc. |
Structure-guided immunotherapy against sars-cov-2
|
CA3180477A1
(en)
|
2020-06-12 |
2021-12-16 |
Elizabeth Alexander |
Antibody therapies for sars-cov-2 infection
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
AU2021296848A1
(en)
|
2020-06-24 |
2023-02-09 |
Humabs Biomed Sa |
Engineered hepatitis B virus neutralizing antibodies and uses thereof
|
KR20230058432A
(ko)
|
2020-08-24 |
2023-05-03 |
암젠 인크 |
약제학적 제형
|
CA3194162A1
(en)
|
2020-09-28 |
2022-03-31 |
Humabs Biomed Sa |
Antibodies against sars-cov-2
|
KR20230104229A
(ko)
|
2020-11-06 |
2023-07-07 |
암젠 인크 |
Cd3에 결합하는 폴리펩티드 구축물
|
EP4240768A2
(de)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Multitargeting bispezifischer antigenbindender moleküle mit erhöhter selektivität
|
JP2023547662A
(ja)
|
2020-11-06 |
2023-11-13 |
アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cldn6及びcd3に選択的に結合するポリペプチド構築物
|
TW202235105A
(zh)
|
2020-11-23 |
2022-09-16 |
美商維爾生物科技股份有限公司 |
抗流感抗體及其組合
|
MX2023005653A
(es)
|
2020-11-23 |
2023-07-31 |
Vir Biotechnology Inc |
Anticuerpos contra los virus de la influenza a.
|
CA3199023A1
(en)
|
2020-11-23 |
2022-05-27 |
Davide Corti |
Broadly neutralizing antibodies against influenza neuraminidase
|
JP2023550785A
(ja)
|
2020-11-25 |
2023-12-05 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
複数のベータコロナウイルスに結合する抗体
|
JP2024502630A
(ja)
|
2021-01-12 |
2024-01-22 |
マーチ セラピューティクス, インコーポレイテッド |
コンテキスト依存性二本鎖dna特異的デアミナーゼ及びその使用
|
CN117222413A
(zh)
|
2021-02-10 |
2023-12-12 |
同润生物医药(上海)有限公司 |
治疗肿瘤的方法和组合
|
WO2022204202A1
(en)
|
2021-03-23 |
2022-09-29 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
CN115141276A
(zh)
|
2021-03-31 |
2022-10-04 |
鸿运华宁(杭州)生物医药有限公司 |
一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用
|
EP4070814A1
(de)
|
2021-04-07 |
2022-10-12 |
Lama France |
Sars-cov-2-polypeptide und verwendungen davon
|
AU2022269312A1
(en)
|
2021-05-06 |
2023-10-19 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
CN117241787A
(zh)
|
2021-06-01 |
2023-12-15 |
安进公司 |
制备冻干蛋白配制品的加速方法
|
CN117377695A
(zh)
|
2021-06-30 |
2024-01-09 |
安进公司 |
冻干制剂的重构方法
|
EP4370535A2
(de)
|
2021-07-15 |
2024-05-22 |
Diogenx |
Rekombinante varianten von r-spondin-proteinen und deren verwendung
|
AR126900A1
(es)
|
2021-08-27 |
2023-11-29 |
Humabs Biomed Sa |
Polipéptidos de coronavirus modificados genéticamente, polinucleótidos, vectores y células huésped, y composiciones relacionadas
|
WO2023034871A1
(en)
|
2021-09-01 |
2023-03-09 |
Vir Biotechnology, Inc. |
High concentration antibody therapies for sars-cov-2 infection
|
CA3230613A1
(en)
|
2021-09-01 |
2023-03-09 |
Daren J. AUSTIN |
Antibody therapies for sars-cov-2 infection in pediatric subjects
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|
WO2023196997A2
(en)
|
2022-04-08 |
2023-10-12 |
2Seventy Bio, Inc. |
Multipartite receptor and signaling complexes
|
WO2023201256A1
(en)
|
2022-04-12 |
2023-10-19 |
Vir Biotechnology, Inc. |
High dose antibody therapies for sars-cov-2 infection
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2023230448A1
(en)
|
2022-05-23 |
2023-11-30 |
Vir Biotechnology, Inc. |
Combination immunotherapy for influenza
|
TW202411246A
(zh)
|
2022-05-23 |
2024-03-16 |
美商維爾生物科技股份有限公司 |
經工程化之b型肝炎病毒中和抗體及其用途
|
WO2023230445A2
(en)
|
2022-05-23 |
2023-11-30 |
Humabs Biomed Sa |
Broadly neutralizing antibodies against influenza neuraminidase
|
WO2023245078A1
(en)
|
2022-06-15 |
2023-12-21 |
Humabs Biomed Sa |
Anti-parvovirus antibodies and uses thereof
|
WO2024006472A1
(en)
|
2022-06-30 |
2024-01-04 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
WO2024015892A1
(en)
|
2022-07-13 |
2024-01-18 |
The Broad Institute, Inc. |
Hla-ii immunopeptidome methods and systems for antigen discovery
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
WO2024026411A1
(en)
|
2022-07-27 |
2024-02-01 |
Humabs Biomed Sa |
Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024047587A1
(en)
|
2022-08-31 |
2024-03-07 |
Regel Therapeutics, Inc. |
Cas-phi compositions and methods of use
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024086827A2
(en)
|
2022-10-20 |
2024-04-25 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
WO2024092033A1
(en)
|
2022-10-26 |
2024-05-02 |
Amgen Inc. |
Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases
|
WO2024108053A1
(en)
|
2022-11-17 |
2024-05-23 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
WO2024112818A1
(en)
|
2022-11-22 |
2024-05-30 |
Humabs Biomed Sa |
Engineered anti-sars-cov-2 antibodies and uses thereof
|
WO2024118998A2
(en)
|
2022-12-01 |
2024-06-06 |
Vir Biotechnology, Inc. |
Engineered anti-sars-cov-2 antibodies and methods of using the same
|